[Effect of schizophyllan in experimental tuberculosis].
D000818:Animals; D000995:Antitubercular Agents / Q000627:therapeutic use*; D001487:Basidiomycota; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000008:administration & dosage / Q000627:therapeutic use; D006025:Glycosaminoglycans / Q000627:therapeutic use*; D008099:Liver / Q000473:pathology; D008168:Lung / Q000473:pathology; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D051379:Mice; D011134:Polysaccharides / Q000008:administration & dosage; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D013154:Spleen / Q000473:pathology; D013307:Streptomycin / Q000008:administration & dosage / Q000627:therapeutic use; D014376:Tuberculosis / Q000188:drug therapy* / Q000473:pathology
D000995:Antitubercular Agents; D006025:Glycosaminoglycans; D011134:Polysaccharides; D004977:Ethambutol; D012293:Rifampin; D013307:Streptomycin